None
Quote | Principia Biopharma Inc. (NASDAQ:PRNB)
Last: | $100.05 |
---|---|
Change Percent: | 0.1% |
Open: | $99.99 |
Close: | $100.05 |
High: | $100.37 |
Low: | $99.95 |
Volume: | 1,792,755 |
Last Trade Date Time: | 09/25/2020 04:55:03 pm |
News | Principia Biopharma Inc. (NASDAQ:PRNB)
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc., a Sanofi company, focused on developing treatments for immune mediated diseases, today announced it has completed patient enrollment into the global Phase 3 PEGASUS trial for rilzabrutinib, an oral inve...
Merger activity increased significantly last week with ten new deals announced. The merger of WPX Energy (WPX) and Devon Energy Corporation (DVN). Morgan Stanley (MS) completes the acquisition of E*TRADE Financial Corporation (ETFC). For further details see: Me...
Message Board Posts | Principia Biopharma Inc. (NASDAQ:PRNB)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Principia Biopharma Inc. Company Name:
PRNB Stock Symbol:
NASDAQ Market:
Principia Biopharma Inc. Website:
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc., a Sanofi company, focused on developing treatments for immune mediated diseases, today announced it has completed patient enrollment into the global Phase 3 PEGASUS trial for rilzabrutinib, an oral inve...
NEW YORK, NY / ACCESSWIRE / September 19, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Maxim Integrated Products, Inc. (NASDAQ: MXIM...
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced that the first patient was dosed in an open label two-arm trial to e...